Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers.

ABSTRACT:

Background

Autistic spectrum disorders (ASD) are severe neurodevelopmental alterations characterised by deficits in social communication and repetitive and restricted behaviours. About a third of patients receive pharmacological treatment for comorbid symptoms. However, 30-50% do not respond adequately and/or present severe and long-lasting side effects.

Methods

Genetic variants in CYP1A2, CYP2C19, CYP2D6 and SLC6A4 were investigated in N = 42 ASD sufferers resistant to pharmacological treatment. Clinical recommendations based on their pharmacogenetic profiles were provided within 24-48 h of receiving a biological sample.

Results

A total of 39 participants (93%) improved after the pharmacogenetic intervention according to their CGI scores (

SUBMITTER: Arranz MJ 

PROVIDER: S-EPMC9143818 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature